Open-label, Multiple Dose, Dose Escalation Study to Evaluate the Safety/Tolerability and Efficacy of EA-2353 in Subjects With Retinitis Pigmentosa

  • End date
    Dec 31, 2023
  • participants needed
  • sponsor
    Endogena Therapeutics, Inc
Updated on 28 October 2022
pupil dilation


This is an open-label, multiple ascending dose study to evaluate the safety, tolerability, and efficacy of EA-2353 in subjects with RP. Unilateral intravitreal injections (IVT) will be administered into the subject's Study Eye. There will be up to 4 cohorts.


This is an open-label, multiple ascending dose study to evaluate the safety, tolerability, and efficacy of EA-2353 in subjects with RP. There will be up to 4 cohorts. Each of the first three cohorts will treat 3 subjects with 4 weekly injections of EA-2353.

Unilateral intravitreal injections (IVT) will be administered into the subject's Study Eye, which is determined as the eye with worse vision based on the BCVA. Eligible subjects will be enrolled into one of the following three cohorts in an ascending sequential fashion:

  • Cohort 1 (low dose)
  • Cohort 2 (mid dose)
  • Cohort 3 (high dose)
  • Cohort 4 (maximum tolerated dose)

Patient participation will last for approximately 7 months.

Condition Retinitis Pigmentosa, Retinitis Pigmentosa Syndrome
Treatment EA-2353
Clinical Study IdentifierNCT05392751
SponsorEndogena Therapeutics, Inc
Last Modified on28 October 2022


Yes No Not Sure

Inclusion Criteria

Male or female, ≥ 18 years of age
Have a clinical and molecular diagnosis of RP
Understand the language of the informed consent and are willing and able to provide written informed consent prior to any study procedures
Are willing to comply with the protocol and follow the instructions including attendance at all scheduled study visits
BCVA in the worse eye between 20/50 and able to count fingers (CF)
Have clear ocular media
Have pupillary dilation sufficient to allow for quality images
Have a central retinal thickness (center point) >100 microns on SD-OCT

Exclusion Criteria

Subjects who are pregnant or suspected to be pregnant and subjects who are lactating or intend to breastfeed. Female subjects of childbearing potential are required to have a negative urine pregnancy test at screening and prior to each injection, and must agree to use an acceptable method of contraception from the time of signing informed consent until the end of the study
Have any uncontrolled systemic disease or non-ocular disorder which would put the subject at risk due to study treatment or procedures, influence the results of the study, or impact the subject's ability to participate in the study (e.g., infection, uncontrolled elevated blood pressure, cardiovascular disease, and inability to maintain glycemic control)
Presence of a significant ocular disease or disorder in the Study Eye
Have a history of any vitreoretinal surgery ever in the Study Eye
Have received any prior cell or gene therapy for RP
Have history or current abuse of alcohol and/or drugs
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note